Royalty Report: Drugs, Arthritis, Cancer – Collection: 233467

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Arthritis
  • Cancer
  • Disease
  • Biotechnology
  • Therapeutic
  • ribonucleic acid
  • Proteins
  • Drug Discovery
  • Antibody
  • Vaccine

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 233467

License Grant
The Licensor Parties have agreed to grant certain rights under their respective patents to Licensee to permit Licensee to commercialize such IL-I Trap product and certain follow-on IL-I Trap products.

Both Licensor Parties grant to Licensee and its Affiliates a non-exclusive license, with a limited right to grant sublicenses, under their respective Licensed Patent Rights to make, have made, use, sell, offer for sale and import Licensed Products in the Field of Use anywhere in the Territory.

License Property
The Licensed Product(s) shall mean a molecule, or gene encoding a molecule, comprising all or an interleukin-1 binding portion of the amino acid sequence for interleukin-1 receptor Type 1 or interleukin-1 receptor Type 2 ( or, in each case, any polypeptide having an amino acid sequence at least 90% identical to all or a portion thereof which itself binds interleukin-1, and, all or an interleukin-I binding portion of the amino acid sequence of a second molecule (exclusive of interleukin-I receptor Type 1, interleukin-1 receptor Type 2 or antibodies which bind interleukin-I, including variants and fragments thereof which bind interleukin-1) that itself binds interleukin-1, or together with any such interleukin-1 binding ammo acid seinquence referred to, participates in the binding of interleukin-1 (including, without limitation, the interleukin-1 receptor accessory protein or a portion thereof (or any polypeptide having an amino acid sequence at least 90% identical to all or a portion thereof)); wherein the molecule is capable of binding of interleukin-1.

Interleukin-1 is a Protein-based drug candidate designed to bind the interleukin-1 (called IL1) cytokine and prevent its interaction with cell surface receptors. IL1 is thought to play a major role in rheumatoid arthritis and other inflammatory diseases.

Field of Use
The Field of Use shall mean all uses of Licensed Product(s).

IPSCIO Record ID: 237243

License Grant
Licensor grants to the United Kingdom Licensee a non-exclusive license, without the right to sublicense, in the territory in the field of use and under the Patent Rights to research, develop, make, have made, use, sell, have sold, offer for sale, have offered for sale, import, and export Licensed Products, and research, develop, use, and practice Licensed Processes only for the purposes of manufacturing or having manufactured the Licensed Products.

Licensor grants a non-exclusive license, without the right to sublicense, in the Territory to conduct preclinical research and/or pre-Phase II clinical trials ( or the equivalent of pre-Phase II clinical trials in the U.S. or other countries) involving the use of Licensed Products in indications outside of the Field of Use.

License Property
The Licensed Product means the first three (3) short consensus repeat protein domains of human complement receptor type 1 (CRI), derivatized to include a myristoyl peptide, having Licensees designation -070 or any successor product of such -070 which is an optimization or derivative of -070, the development, manufacture, use, sale, offer for sale, importation or distribution.
Field of Use
The field of use means the treatment of rheumatoid arthritis.

IPSCIO Record ID: 329687

License Grant
The Swiss Licensor, an international non-profit cancer research organization, grants to Licensee an exclusive license under the Licensed Patent Rights to research, develop, make, have made, import have imported. use. have used, sell, have sold, offer for sale, have offered for sale and otherwise exploit Licensed Products in the Field throughout the world.
License Property
Licensed Product means any products the making, selling, using or importing of which is covered by a Valid Claim of a Licensed Patent Right and is (i) an ALK-1 Receptor Product; (ii) an ALK-1 Antibody Product; (iii) an ALK-2 Receptor Product; (iv) an ALK-3 Receptor Product; (v) an ALK-3 Antibody Product; (vi) an ALK4 Receptor Product; (vii) an ALK-4 Antibody Product (viii) an ALK-5 Receptor Product (ix) an ALK-5 Antibody Product; (x) an ALK-6 Receptor Product; (xi) an ALK-6 Antibody Product.

ALK-1 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-1 receptor, as exemplified by amino acids 1-118 of the human ALK-1 sequence presented in U.S. Patent No. 6,316217, or an active po11ion thereof.

ALK-1 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-1 receptor.

ALK-2 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-2 receptor, as exemplified by amino acids 1-124 of the human ALK-2 sequence presented in C .S. Patent No. 6,316,217 or an active portion thereof.

ALK-3 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-3 receptor, as exemplified by amino acids 1-152 of the human ALK-3 sequence presented in U.S. Patent  6.316,217, or an active portion thereof.

ALK-3 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-3 receptor.

ALK-4 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-4 receptor, as exemplified by amino acids 1-126 of the human ALK-4 sequence presented in U.S. Patent No. 6,316,217, or an active portion thereof.

ALK-4 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-4 receptor.

ALK-5 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-5 receptor, as exemplified by amino acids 1-121 of the human ALK-5 sequence presented in U.S. Patent No. 6,316.217, or an active portion thereof.

ALK-5 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-5 receptor.

ALK-6 Receptor Product means any product which is comprised at!east in part of an extracellular domain of an ALK-6 receptor, as exemplified by amino acids 1-122 of the murine ALK-6 sequence presented in U.S. Patent No. 6,316,217, or an active portion thereof.

ALK-6 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-6 receptor.

Field of Use
The patent rights relate to the first cloning of the type I activin receptors, as well as the treatment of pancreatic tumors with dalantercept.

IPSCIO Record ID: 26674

License Grant
The University grants to the Company, (i) an exclusive license under the licensed Patents to develop, manufacture, have made, import, use, sell, have sold, distribute, rent or lease Licensed Products/Services throughout the Territory, together with a right to grand sublicenses.
License Property
Certain patent applications titled Nucleic Acids and Proteins of Insect or 83b odorant receptor genes and uses thereof.” The olfaction intellectual property assets are also referred to herein as “our olfaction intellectual property.

IPSCIO Record ID: 29300

License Grant
The Licensor announced that it had entered into a royalty Agreement with the Licensee that replaced a previous collaboration and License Agreement for a second-generation interleukin-1 Trap, should the Licensee decide to proceed in the development of this Trap.
License Property
Interleukin-1 (IL-1) is a protein secreted by certain cells in the body.  In many cases, IL-1 acts as a messenger to help regulate immune and inflammatory responses by attaching to cell-surface receptors in cells that participate in the body's immune system. In excess, it can be harmful and has been shown to be a key driver of inflammation in a variety of diseases.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 286023

License Grant
The Licensor of England grants a right and license to develop, make, have made, use, offer for sale, sell, have sold, import and export Licensed Products for use in the Field in the Territory.  

The license s exclusive or non-exclusive on a patent by patent basis.

License Property
Licensor has a product, known as Cxx-870, which contains a recombinant humanized pegylated Fab’ antibody fragment which binds to TNF alpha, or Tumor Necrosis Factor? alpha.

Licensed Product means any product that contains or comprises an Antibody, or any chemically modified Antibody, which recognizes TNF alpha. For the avoidance of doubt, Licensed Product shall not include non-Antibody inhibitors of TNF alpha.

The patents are titled Multichain Polypeptides or Proteins and Processes for their Production;
Recombinant Antibody; Humanized Antibodies; Protein Expression System;  Process for obtaining Antibodies; Monovalent Antibody Fragments;  and, Biological Products.

Field of Use
Field means the prevention, treatment, diagnosis or control of all diseases or conditions in humans or animals; provided, however, that with respect to CDP-571, the Field shall not include the prevention, treatment, diagnosis or control of any diseases or conditions other than rheumatoid arthritis.

IBD Indication means the prevention, treatment or control of Crohn’s Disease and/or ulcerative colitis in humans and/or animals.

RA Indication means the prevention, treatment or control of rheumatoid arthritis in humans.

IPSCIO Record ID: 332237

License Grant
Licensor hereby grants to Canadian Licensee and Licensee hereby accepts a non-exclusive license under Licensed Patents during the Term to research, develop, make (and have made), use, sell, offer for sale, and import Licensed Product in the Territory in the Field of Use.  Licensee shall have a right to grant sublicenses.
License Property
Licensed Patents shall mean (a) US Patent Nos. 6,579,520 and 6,569,645, (b) any patents issuing from continuations, divisions, or continuations-in-part from which any of the foregoing claim priority, and (c) invention certificates, substitutions, reissues, reexaminations, extensions, registrations, patent term extensions, supplementary, supplementary protection certificates, renewals and foreign counterparts of any of the foregoing (a) or (b), including without limitation EP 1240325, and CA 2391374.

6,579,520 – IL-17 related mammalian cytokine polypeptides (IL-17E)
6,569,645 – IL-17 homologous polypeptides and therapeutic uses thereof

Licensee Protein means a IL-17E protein for which either (a) the research and/or at least one Clinical Trial was significantly conducted by Licensee either on its own, or together and in
collaboration with a Sublicensee or (b) Licensee and/or its Sublicensees have exclusive marketing rights worldwide.

Field of Use
Field of Use means treatment of human cancer.

IPSCIO Record ID: 260433

License Grant
The purpose of this agreement is to exclusively collaborate on the development of one or more products binding to and inhibiting the activity of GM-CSF.

The German Licensor grants to the German Licensee an exclusive license, with the right to grant sublicenses, to the Licensed Technology, other than the Sublicensed Patents and the Sublicensed Know-How, to conduct research and development, make, have made, use, Commercialize, and import the Products in the Field in the Territory.

Licensor grants an exclusive sublicense, with the right to grant further sublicenses, under the rights and licenses granted to Licensor in the Upstream Agreements with respect to the Sublicensed Technology, to research, develop, Commercialize, make, have made, use, offer for sale, sell, and import the Products in the Field in the Territory.

This agreement includes a non-exclusive grant beck from Licensee to Licensor.

License Property
Licensor is developing the MT203 Product, an anti-GM-CSF IgG1 antibody.

GM-CSF means the whole or part and natural variants of the granulocytemacrophage colony stimulating factor (GM-CSF) identified by the SWlSS-PROT entry name CSF2 _ HUMAN and accession number P04141 with the amino acid sequence as defined.

MT203 Product means any pharmaceutical product comprising the IgG1 antibody with the variable domain amino sequence.

The patents are for Antibody neutralizers of human granulocyte macrophage colony stimulating factor; and,  Method of identifying binding site domains that retain the capacity of binding to an epitope.

Field of Use
The Field means the treatment of human diseases and conditions.   The MT203 human antibody neutralizing the activity of granulocyte macrophage colony – stimulating factor (GM-CSF),  has potential applications in the treatment of inflammatory and autoimmune diseases.

IPSCIO Record ID: 369382

License Grant
For the Exclusive Licenses, Licensor grants
–  an exclusive license, including the right to sublicense, under the Licensor Patent Rights, to research, develop, make, have made, use, sell, offer for sale, supply, cause to be supplied and import Compounds and Licensed Products in the Territory;
–  an exclusive license, including the right to sublicense, to use Licensor Technology and Confidential information in connection with the research. development, making, having made, use, sale, oiler for sale, supply, causing to be supplied and importation of Compounds and Licensed Products in the Territory;
–  an exclusive license, including the right to sublicense, under the Licensor Patent Rights to research, develop, make, have made, use, sell, offer for sale, supply, cause to be supplied and import Diagnostic Assays in the Territory; and
–  an exclusive license, including the right to sublicense, to use Licensor Technology and Confidential information in connection with the research, development, making, having made, use, sale, offer for sale, supply, causing to be supplied and importation of Diagnostic Assays in the Territory.

For the Non-Exclusive Research License, Licensor grants a non-exclusive, irrevocable, perpetual license in the Territory, with the right to sublicense to Affiliates, to use for all research purposes the Licensor Technology and Confidential Information disclosed to Licensee during the Term, excluding any Patent Rights relating thereto.

License Property
Licensor owns or otherwise controls certain patents, patent applications, technology, know-how and scientific and technical information relating to an EGFRvIII mutant peptide comprising the amino acid sequence LYS-LYS-GLY-ASN-TYR.

CDX-110 means the EGFRvlll mutant peptide consisting of the amino acid sequence LEU-GLU-GLU-LYS-LYS-GLY-ASN-TYR-V AL-V AL-THR-ASP-HIS covalently linked to a Cysteine and conjugated to keyhole limpet hemocyanin (KLH).  CDX-110 is a therapeutic cancer vaccine candidate.

Compound means a peptide that comprises at least a portion of an EGFRvIII comprising the amino acid sequence LYS-LYS-GLY-ASN-TYR. as an antigen. alone or as a component of a larger peptide. protein or molecule.

EGFRvIII means EGFR variant III peptide, a variant of EGFR. previously referred to as a type II variation of EGFR, consisting of the amino acid sequence of EGFR as set forth in GenBank Accession No, CAA2524Q. except amino acids number 1 through 24 have been deleted and where amino acids number 30 through 297 have been replaced by a Glycine. and naturally occurring variants thereof.

Additional Component means a therapeutically active (alone or in combination) adjuvant. immunomodulator. immunoregulator or hapten.

APC Product means an antibody or fragment thereof. that is targeted to an antigen-presenting cell (APC) and that comprises or is connected to a Compound or Licensed Product.

Patents are for the EGFRvlll Patent Family 1, 2, and 3.

Field of Use
The field of use for CDX-110 includes the treatment of glioblastoma multiforme or GBM.

Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive type of cancer that begins within the brain.

Rindopepimut is an experimental therapeutic cancer vaccine that targets the tumor-specific molecule epidermal growth factor receptor variant III (EGFRvIII) in patients with Glioblastoma Multiforme (GBM)

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.